human
rhinovirus
hrv
respiratori
virus
belong
famili
picornavirida
genu
enteroviru
hrv
first
isol
remain
lead
caus
upper
respiratori
tract
infect
worldwid
price
jacob
et
al
hrv
remain
primari
etiolog
agent
common
cold
respons
signific
morbid
medic
cost
absenc
school
workplac
fendrick
et
al
pappa
et
al
gern
van
der
zalm
et
al
jacob
et
al
annual
econom
cost
associ
hrv
infect
like
exceed
billion
dollar
per
year
fendrick
et
al
hrv
infect
occur
yearround
part
world
exhibit
season
peak
spring
andor
autumn
winther
et
al
miller
et
al
jacob
et
al
litwin
bosley
leott
et
al
addit
caus
upper
respiratori
infect
hrv
also
link
develop
shown
exacerb
asthma
lower
respiratori
tract
infect
human
asthmat
volunt
hick
et
al
malmstrom
et
al
renwick
et
al
jackson
et
al
messag
et
al
gern
jacob
et
al
saraya
et
al
signific
health
burden
associ
hrv
continu
highlight
dire
need
hrv
vaccin
yet
sever
challeng
preclud
efficaci
vaccin
develop
rhinovirus
among
common
viral
infecti
agent
found
human
hrv
account
upper
respiratori
tract
infect
infect
rate
among
young
children
high
time
year
arruda
et
al
turner
pappa
et
al
hrv
infect
gener
associ
incub
period
day
follow
symptomat
period
week
clearanc
pappa
et
al
asymptomat
infect
nasopharynx
quit
common
rhinovirus
especi
among
young
children
van
benten
et
al
iwan
et
al
upper
respiratori
tract
infect
associ
common
coldlik
symptom
includ
rhinorrhea
sore
throat
cough
sneez
nasal
congest
gener
malais
arruda
et
al
jacob
et
al
addit
common
cold
rhinoviru
infect
often
link
acut
otiti
media
rhinosinus
also
frequent
coincid
bacteri
coinfect
pitkaranta
et
al
alper
et
al
jackson
et
al
jacob
et
al
despit
optim
temperatur
hrv
replic
cooler
surfac
upper
respiratori
tract
rhinovirus
also
implic
lower
respiratori
diseas
includ
pneumonia
bronchiti
bronchiol
exacerb
asthma
mcfadden
et
al
turner
papadopoulo
et
al
renwick
et
al
gern
half
asthma
exacerb
incid
known
associ
hrv
infect
earli
hrv
infect
result
wheez
promot
greater
risk
asthma
develop
later
life
gern
buss
gern
et
al
hayden
jackson
et
al
dougherti
fahi
approxim
children
hospit
acut
asthma
attack
shown
detect
hrv
bizzintino
et
al
furthermor
studi
evalu
patient
admit
wheez
identifi
nearli
half
test
posit
hrv
heymann
et
al
collect
studi
demonstr
hrv
though
typic
consid
pathogen
high
mortal
high
potenti
acut
respiratori
ill
potenti
promot
exacerb
chronic
respiratori
health
condit
transmiss
hrv
occur
primarili
individu
either
direct
contact
contact
fomit
aerosol
gwaltney
hendley
gwaltney
et
al
dick
et
al
jen
dick
hendley
gwaltney
rhinovirus
capabl
remain
infecti
surfac
outsid
host
hour
result
high
potenti
spread
infect
uninfect
individu
hendley
et
al
suscept
sever
infect
reinfect
link
mani
environment
genet
factor
includ
poor
interferon
respons
exist
allergi
asthma
exposur
air
pollut
includ
tobacco
smoke
poor
diet
stress
gern
kang
et
al
jacob
et
al
rate
reinfect
specif
type
hrv
suggest
case
hrv
infect
compet
immun
fail
develop
preexist
immun
maintain
papi
et
al
human
rhinoviru
nonenvelop
viru
positivesens
singlestrand
rna
ssrna
approxim
kb
encod
protein
figur
palmenberg
et
al
palmenberg
gern
viral
capsid
hrv
compris
four
viral
protein
vp
remain
viral
protein
respons
viral
replic
subsequ
assembl
antigen
variat
among
hrv
type
deriv
variat
expos
surfac
embed
respons
rna
packag
assembl
figur
compar
rest
hrv
genom
capsid
protein
exhibit
high
degre
heterogen
result
wide
rang
antigen
divers
glanvil
johnston
lewisrog
et
al
sever
antigen
site
identifi
hrv
strain
studi
bind
neutral
antibodi
howev
locat
site
often
conserv
sherri
rueckert
sherri
et
al
appleyard
et
al
mediat
cell
surfac
attach
engag
varieti
cell
surfac
receptor
figur
palmenberg
gern
blaa
tradit
major
hrv
type
known
bind
intercellular
adhes
molecul
receptor
minor
hrv
type
util
lowdens
lipoprotein
receptor
ldlr
bind
staunton
et
al
hofer
et
al
palmenberg
howev
recent
identif
specif
variant
cadherinrel
famili
member
primari
receptor
hrv
c
speci
breadth
circul
hrv
type
yettob
identifi
receptor
may
also
exist
bochkov
et
al
palmenberg
hrv
may
enter
cell
sever
pathway
includ
macropinocytosi
clathrindepend
clathrinindepend
endocytosi
blaa
upon
entri
uncoat
viral
genom
translat
subsequ
proteolyt
process
virusencod
proteas
fuch
blaa
virion
assembl
genom
packag
unit
capsid
protein
associ
unit
capsid
protein
per
face
form
icosahedr
structur
encapsul
rna
genom
viru
rossmann
et
al
palmenberg
et
al
liu
et
al
three
speci
rhinoviru
current
known
hrva
hrvb
hrvc
howev
sequenc
serolog
method
defin
approxim
hrva
type
hrvb
type
hrvc
type
potenti
mani
serolog
distinct
hrv
type
circul
figur
palmenberg
et
al
mcintyr
et
al
rhinoviru
strain
within
given
speci
share
greater
amino
acid
ident
new
type
classifi
almost
exclus
base
sequenc
align
palmenberg
gern
isol
share
greater
ident
may
merg
exist
type
mcintyr
et
al
palmenberg
gern
major
challeng
develop
hrv
vaccin
subsequ
establish
protect
immun
phylogenet
breadth
exist
hrv
serotyp
infect
one
type
hrv
unlik
afford
immun
type
result
lifelong
infect
differ
hrv
type
exposur
howev
limit
crossserotyp
protect
demonstr
closelyrel
type
cooney
et
al
glanvil
johnston
among
known
type
hrv
hrva
hrvc
gener
associ
sever
diseas
asthma
exacerb
hrvb
miller
et
al
piralla
et
al
bochkov
et
al
lee
et
al
structur
three
speci
exhibit
distinct
surfac
pocket
differ
may
account
phenotyp
differ
palmenberg
gern
liu
et
al
hrvc
recent
identifi
sinc
recogn
major
contributor
hrv
diseas
arden
et
al
lamson
et
al
kistler
et
al
renwick
et
al
dominguez
et
al
half
hrv
infect
young
infant
recogn
hrvc
strain
bochkov
et
al
furthermor
among
hrv
type
detect
childhood
acut
asthma
episod
hrvc
frequent
detect
speci
bizzintino
et
al
follow
initi
identif
nearli
type
identifi
classifi
distinct
speci
hrv
hrva
hrvb
simmond
et
al
mcintyr
et
al
palmenberg
gern
howev
unlik
hrva
hrvb
studi
hrvc
strain
complic
inabl
initi
grow
virus
cell
cultur
first
report
describ
success
recoveri
hrvc
type
via
revers
genet
howev
virus
could
subsequ
passag
bochkov
et
al
unlik
counterpart
hrvc
type
use
ldlr
primari
receptor
attach
bochkov
et
al
phenotyp
hrvc
may
toler
higher
temperatur
replic
result
lower
respiratori
tract
diseas
speci
b
ashraf
et
al
furthermor
viru
could
readili
passag
cultur
recent
identif
primari
receptor
viru
bochkov
et
al
first
capsid
structur
hrvc
type
soon
follow
liu
et
al
combin
cultiv
revers
genet
approach
consider
attent
given
studi
hrvc
biolog
recent
work
shown
hrvc
select
target
ciliat
airway
epitheli
cell
express
grigg
et
al
find
encourag
pave
way
thorough
studi
hrvc
biolog
potenti
develop
hrvcspecif
antivir
vaccin
due
signific
role
human
diseas
develop
effect
rhinoviru
vaccin
common
cold
need
includ
antigen
coverag
repres
hrvc
strain
develop
vaccin
rhinoviru
remain
univers
hope
public
health
scientif
commun
half
centuri
prospect
develop
hrv
vaccin
remain
bleak
remain
mani
technic
logist
fundament
biolog
challeng
develop
success
vaccin
hrv
mice
cotton
rat
import
model
test
efficaci
vaccin
elicit
neutral
antibodi
howev
fulli
permiss
infect
resembl
aspect
hrv
pathogenesi
human
bartlett
et
al
blanco
et
al
recent
advanc
produc
mice
transgen
human
made
improv
model
studi
hrv
infect
bartlett
et
al
yet
vaccin
prepar
would
like
studi
directli
human
unlik
mani
human
viral
pathogen
shear
breadth
serolog
distinct
type
hrv
present
uniqu
difficult
challeng
vaccin
design
order
develop
hrv
vaccin
regardless
approach
eg
liveattenu
inactiv
one
vaccin
prepar
must
abl
elicit
protect
neutral
antibodi
potenti
serolog
distinct
type
span
three
differ
speci
despit
advanc
cell
cultur
result
increas
titer
viru
shear
technic
challeng
produc
suffici
quantiti
qualiti
antigen
cover
breadth
hrv
type
remain
key
technic
challeng
addit
remain
insuffici
surveil
epidemiolog
data
accur
identifi
specif
domin
hrva
hrvc
type
priorit
vaccin
prepar
mitig
diseas
furthermor
sever
studi
use
antivir
antigen
peptid
prepar
viru
report
induct
escap
mutat
often
singl
amino
acid
heinz
et
al
appleyard
et
al
speller
et
al
howev
structur
major
hrv
type
yet
resolv
recent
first
hrvc
structur
determin
liu
et
al
despit
clear
challeng
advanc
understand
develop
hrv
vaccin
feasibl
induc
last
protect
immun
becam
evid
mani
serolog
distinct
strain
rhinoviru
exist
develop
polyval
vaccin
prepar
would
requir
combat
common
cold
mitchison
earli
attempt
develop
hrv
vaccin
focus
whether
liveattenu
inactiv
hrv
strain
induc
antibodi
capabl
afford
protect
heterolog
diverg
strain
could
induc
broad
protect
lastli
multival
vaccin
prepar
could
efficaci
studi
byno
et
al
demonstr
individu
capabl
protect
level
antisera
specif
strain
hrv
two
followup
studi
publish
demonstr
singl
strain
either
liveunattenu
hrv
hrv
inactiv
formalin
heat
capabl
induc
antibodi
follow
intramuscular
inject
circul
antibodi
level
correl
invers
associ
ill
doggett
et
al
mufson
et
al
mitchison
evid
vaccin
strain
hrv
capabl
induc
protect
antibodi
also
may
provid
homolog
protect
strain
subsequ
studi
publish
next
year
support
hrv
vaccin
could
efficaci
last
immun
follow
homolog
challeng
heterolog
strain
perkin
et
al
b
buscho
et
al
earli
first
studi
evalu
crossneutr
serolog
reactiv
mani
hrv
type
publish
open
door
earliest
attempt
polyval
vaccin
prepar
cooney
et
al
demonstr
rabbit
antisera
type
result
limit
crossneutr
least
five
type
studi
earlier
studi
use
monoval
prepar
led
first
major
attempt
polyval
vaccin
hrv
hamori
et
al
time
hrv
type
describ
sever
other
vari
stage
confirm
studi
hamori
et
al
produc
two
separ
decaval
hrv
vaccin
prepar
combin
formalininactiv
uniqu
set
type
initi
titer
unfortun
vaccin
prepar
result
low
titer
neutral
antibodi
detect
host
respons
less
input
type
compar
known
number
type
time
develop
effect
polyval
vaccin
soon
regard
improb
imposs
fox
couch
next
year
scientif
advanc
cellular
molecular
biolog
continu
research
hrv
biolog
typespecif
differ
led
renew
interest
hope
develop
hrv
vaccin
first
capsid
hrv
crystal
structur
resolv
rossmann
et
al
structur
three
speci
hrv
would
soon
determin
structur
deposit
protein
data
bank
pdb
palmenberg
palmenberg
et
al
full
genom
sequenc
publish
signific
number
known
hrva
hrvb
strain
provid
new
insight
hrv
evolut
specificstrain
differ
strong
evid
recombin
antigen
type
light
daunt
task
develop
polyval
inactiv
vaccin
prepar
type
advanc
understand
hrv
structur
recent
effort
focus
identifi
exploit
conserv
antigen
site
subunit
andor
tcell
base
approach
sever
recent
attempt
use
immunogen
demonstr
crossserotyp
reactiv
antibodi
gener
enough
exposur
recombin
may
potenti
antigen
induct
limit
crossreact
edlmayr
et
al
mclean
et
al
furthermor
studi
also
shown
nterminu
capabl
elicit
crossserotyp
antibodi
katpal
et
al
panjwani
et
al
effort
field
influenza
shown
promot
recognit
immun
base
intern
epitop
express
cell
effect
target
conserv
epitop
afford
greater
activ
crossserotyp
protect
lee
et
al
hillair
et
al
earlier
studi
hrv
demonstr
cell
popul
recogn
share
type
specif
epitop
hast
et
al
b
gern
et
al
express
recombin
combin
adjuv
combin
incomplet
fruend
cpg
effect
promot
strong
crossserotyp
antibodi
respons
glanvil
et
al
collect
studi
provid
demonstr
develop
subunit
vaccin
may
effect
approach
address
hrv
antigen
divers
vaccin
prepar
addit
studi
illustr
crossreact
antigen
use
specif
adjuv
may
use
increas
serolog
breadth
hrv
coverag
limit
number
type
antigen
necessari
effort
examin
whole
viru
prepar
continu
use
explor
potenti
vaccin
prepar
blanco
et
al
intramuscular
administr
live
shown
induc
crossserotyp
neutral
antibodi
respons
intranas
challeng
cotton
rat
last
year
inactiv
vaccin
prepar
compris
type
repres
divers
known
hrva
strain
shown
induc
neutral
antibodi
one
type
test
follow
boost
rhesu
macaqu
lee
et
al
studi
lee
et
al
also
demonstr
use
reconstitut
decaval
vaccin
prepar
hamori
et
al
studi
pitfal
earli
polyval
vaccin
effort
like
combin
inadequ
antigen
level
potenti
need
adjuv
recent
find
illustr
high
valenc
polyval
vaccin
prepar
would
like
necessari
hrv
vaccin
may
effect
promot
last
immun
provid
suffici
antigen
level
present
much
last
centuri
hrv
vaccin
often
regard
imposs
multival
vaccin
prepar
pathogen
valenc
necessari
afford
protect
circul
hrv
yet
demonstr
commerci
vaccin
yet
advanc
understand
hrv
type
capsid
structur
recent
advanc
identifi
conserv
crossreact
antigen
site
shed
new
light
direct
explor
vaccin
design
furthermor
advanc
hrv
revers
genet
potenti
creat
chimer
viru
prepar
collect
suggest
develop
hrv
vaccin
technic
imposs
requir
novel
ingenu
continu
studi
exist
similar
differ
among
hrv
type
contribut
directli
write
draft
edit
final
approv
articl
submiss
cs
jn
mm
mm
cofound
meissa
vaccin
inc
serv
chief
scientif
offic
compani
mm
inventor
patent
applic
describ
rhinoviru
vaccin
describ
herein
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
